ORCL Stock Study (10-24-26)
Posted by Mark on November 17, 2026 at 06:53 | Last modified: October 24, 2026 14:34I recently studied Oracle Corp. (ORCL, $126.15).
M* writes:
> Oracle provides enterprise applications and infrastructure
> offerings through a variety of flexible IT deployment models,
> including on-premises, cloud-based, and hybrid. Founded in
> 1977, Oracle pioneered the first commercial SQL-based
> relational database management system, which is commonly
> used by the world’s largest companies for high-volume online
> transaction processing workloads. Besides databases, Oracle
> also sells enterprise resource planning platforms and cloud
> infrastructure that play an increasingly important role in
> large language model training and inferencing.
Over the past decade, this mega-size (over $50B annual revenue) company has grown sales and EPS at annualized rates of 6.3% and 13.0%, respectively (FY ends May 31; calendar year from BI website incremented by one to match). Lines are mostly up, straight, and parallel except for sales dips in ’19 and ’20 along with EPS declines in ’18 and ’22. Ten-year EPS R^2 is 0.52, but Value Line (VL) gives an Earnings Predictability score of 100. Shares outstanding decrease 30.9% (4.0% per year).
Over the past decade, PTPM trails peer and industry averages while ranging from 18.0% in ’22 to 32.4% in ’18 with a last-5-year mean of 22.4%. ROE leads peer and industry averages despite being [NMF] high, triple digits, or negative in different years due mainly to massive share buybacks (see above). Last-5-year-ROE mean is -22.6% (shareholder equity has been choppy about the zero line with a mean decrease of 2.6%/year). Debt-to-capital is greater than peer and industry averages with a last-5-year mean of 92.2% (these last three sentences make my head hurt).
Quick ratio is 1.02 and interest coverage 5.1 per M* who assigns “Narrow” Economic Moat, “Standard” Capital Allocation, and a C grade for Financial Health (per BI website). VL gives an A rating for Financial Strength.
RightStock—a new tool on the BI website that I am tracking for informational purposes—gives a fitness score of 70 (“moderate,” citing poor ROE and poor debt-to-capital) and opportunity score of 100 (“excellent”).
With regard to sales growth:
- YF gives YOY ACE 34.2% and 45.7% for ’27 and ’28, respectively (based on 39 analysts).
- Zacks gives YOY ACE 34.3% and 44.1% for ’27 and ’28, respectively (13 analysts).
- VL projects 32.1% per year from ’26-’30.
- CFRA projects 34.2% YOY and 40.1% per year for ’27 and ’26-’28, respectively.
- M* gives 2-year annualized ACE of 41.2% and projects 31.4% per year from ’26-’31 in Equity Report.
>
My 12.0% forecast is well below the range.
With regard to EPS growth:
- MarketWatch gives ACE 21.3% and 27.3% per year for ’26-’28 and ’26-’29 (based on 45 analysts).
- Nasdaq.com gives ACE 36.1% YOY and 36.2% per year for ’28 and ’27-’29 (16 / 12 / 4 analysts for ’27 / ’28 / ’29).
- Seeking Alpha projects 4-year annualized growth of 30.2%.
- Argus projects 2-year annualized 26.0% and 5-year annualized of 9.0% [see a problem here?].
- Finviz gives 5-year annualized ACE of 26.5% (8).
- LSEG has LTG at 25.8%.
- YF gives YOY ACE of 6.6% and 35.0% for ’27 and ’28, respectively (37).
- Zacks gives YOY ACE 6.5% and 33.5% for ’27 and ’28 along with 5-year annualized 21.1% (13).
- VL projects 21.5% per year from ’26-’30.
- CFRA projects 6.2% YOY and 19.9% per year for ’27 and ’26-’28, respectively.
- M* gives long-term annualized ACE of 22.0% and projects 23.4% per year from ’26-’31 in Equity Report.
>
My 12.0% per year forecast is near [at, really] bottom of the long-term-estimate range (mean of eight: 22.4%). Initial value is ’26 EPS of $5.83/share rather than 2027 Q1 $6.38 (TTM).
My Forecast High P/E is 24.0. Over the past 10 years, high P/E ranges from 17.7 in ’21 to 45.7 in ’25 (excluding upside outliers 59.4 and 59.3 in ’18 and ’26, respectively) with last-5-year mean of 40.1 and a last-5-year-mean average P/E of 32.5. I am lowest since ’21 and below the 10-year median (28.0 with outliers excluded).
My Forecast Low P/E is 16.0. Over the past 10 years, low P/E ranges from 11.2 in ’21 to 27.7 in ’22 (excluding 48.6 in ’18) with a last-5-year mean of 24.9. I am forecasting lowest since ’21 (14.3 in ’19, 12.9 in ’20, and ’21 are less).
My Low Stock Price Forecast (LSPF) of $93.30 is default based on initial value from above: 26.0% less than previous close and 18.5% less than the 52-week low.
Over the last decade, payout ratio (PR) ranges from 22.9% in ’21 to 84.4% in ’18 with a last-5-year mean of 42.8%. I am forecasting below the range at 22.0%.
These inputs land ORCL in the BUY zone with a U/D ratio of 3.8. Total Annualized Return (TAR) is 15.4%.
PAR (using Forecast Average—not High—P/E) of 11.4% is decent for a mega-size company. If a solid margin of safety (MOS) backs this study, then I can proceed based on TAR instead.
To assess MOS, I start by comparing my inputs with those of Member Sentiment (MS). Based on 87 studies done in the past 90 days (my study and 29 other outliers excluded), averages (lower of mean/median) for projected sales growth, projected EPS growth, Forecast High P/E, Forecast Low P/E, and PR are 22.0%, 17.9%, 32.9, 22.2, and 41.3% respectively. I am lower across the board. VL projects a future average P/E of 23.0 that is less than MS (25.7) and greater than mine (20.0).
MS high / low EPS are $14.01 / $5.75 versus my $10.27 / $5.83 (per share). My high EPS is less due to a lower growth rate. VL (M*) high EPS of $16.65 ($18.87) is greater than both (not to mention 4-year forecasts rather than our five).
MS LSPF of $114.50 implies a Forecast Low P/E of 19.9: less than the above-stated 22.2. MS LSPF is 10.3% less than the default $5.75/share * 22.2 = $127.65 (INVALID on today’s date) resulting in more conservative zoning. MS LSPF is still 22.7% greater than mine.
MOS is robust in the study because my inputs are below/near most historical/analyst/MS estimates and ranges. Supporting the MOS is MS TAR exceeding mine by 12.4% (unreasonably high) per year and my substantially lower LSPF.
With regard to valuation, PEG is 0.74 and 1.5 per Zacks and my projected P/E: fairly valued (3.1 per M* just seems wrong). Relative Value [(current P/E) / 5-year-mean average P/E] is quite cheap at 0.61. “Quick and dirty” cash flow has stock undervalued by 69% (rejecting Google AI’s guidance by excluding dividend). M* reports stock at a 35% discount.
Per my SSG, ORCL is a U/D BUY right now under $131 share. [246.5 / ((13.97 / 100 ) +1 ) ^ 5] ~ $128 meets the BetterInvesting® TAR criterion given forecast high price ~$247.
A 90-day free trial to BetterInvesting® may be secured here (also see link under “Pages” section at top right of this page).
Categories: BetterInvesting® | Comments (0) | Permalink